作者
Sabine Venderbosch, Iris D Nagtegaal, Tim S Maughan, Christopher G Smith, Jeremy P Cheadle, David Fisher, Richard Kaplan, Philip Quirke, Matthew T Seymour, Susan D Richman, Gerrit A Meijer, Bauke Ylstra, Danielle AM Heideman, Anton FJ de Haan, Cornelis JA Punt, Miriam Koopman
发表日期
2014/10/15
期刊
Clinical Cancer Research
卷号
20
期号
20
页码范围
5322-5330
出版商
American Association for Cancer Research
简介
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR) status and its relation to BRAF mutation (BRAFMT) status in metastatic colorectal cancer (mCRC).
Experimental Design: A pooled analysis of four phase III studies in first-line treatment of mCRC (CAIRO, CAIRO2, COIN, and FOCUS) was performed. Primary outcome parameter was the hazard ratio (HR) for median progression-free survival (PFS) and overall survival (OS) in relation to MMR and BRAF. For the pooled analysis, Cox regression analysis was performed on individual patient data.
Results: The primary tumors of 3,063 patients were analyzed, of which 153 (5.0%) exhibited deficient MMR (dMMR) and 250 (8.2%) a BRAFMT. BRAFMT was observed in 53 (34.6%) of patients with dMMR tumors compared with 197 (6.8%) of patients with proficient MMR (pMMR) tumors (P < 0.001). In the …
学术搜索中的文章
S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith… - Clinical Cancer Research, 2014